Vertex Pharmaceuticals Incorporated (VRTX) Income Statement Analysis

See more : Element Nutritional Sciences Inc. (ELMT.CN) Income Statement Analysis – Financial Results

Complete financial analysis of Vertex Pharmaceuticals Incorporated (VRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex Pharmaceuticals Incorporated, a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Fuso Chemical Co.,Ltd. (4368.T) Income Statement Analysis – Financial Results
Population Health Investment Co., Inc. (PHICU) Income Statement Analysis – Financial Results
Maiden Holdings North America, Ltd. (MHNC) Income Statement Analysis – Financial Results
Borosil Renewables Limited (BORORENEW.BO) Income Statement Analysis – Financial Results
Kenedix Retail REIT Corporation (3453.T) Income Statement Analysis – Financial Results

Vertex Pharmaceuticals Incorporated (VRTX)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.vrtx.com

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990
Revenue	9.87B	8.93B	7.57B	6.21B	4.16B	3.05B	2.49B	1.70B	1.03B	580.42M	1.21B	1.53B	1.41B	143.37M	102.05M	175.50M	199.01M	216.36M	160.89M	102.72M	69.14M	161.09M	167.49M	78.13M	61.60M	44.40M	43.80M	13.30M	22.10M	19.60M	27.90M	3.80M	3.20M	2.30M
Cost of Revenue	1.26B	1.08B	904.20M	736.30M	547.76M	409.54M	275.12M	210.46M	125.54M	60.99M	130.28M	279.89M	80.51M	12.73M	14.20M	15.69M	13.90M	12.17M	10.10M	5.65M	3.13M	28.28M	39.63M	4.08M	-3.40M	-4.50M	-3.60M	-3.20M	-3.70M	-3.50M	-3.90M	-2.80M	-1.80M	0.00
Gross Profit	8.61B	7.85B	6.67B	5.47B	3.62B	2.64B	2.21B	1.49B	906.79M	519.43M	1.08B	1.25B	1.33B	130.64M	87.85M	159.82M	185.11M	204.19M	150.79M	97.07M	66.02M	132.80M	127.86M	74.05M	65.00M	48.90M	47.40M	16.50M	25.80M	23.10M	31.80M	6.60M	5.00M	2.30M
Gross Profit Ratio	87.21%	87.90%	88.06%	88.14%	86.84%	86.56%	88.95%	87.64%	87.84%	89.49%	89.25%	81.67%	94.29%	91.12%	86.08%	91.06%	93.01%	94.38%	93.72%	94.50%	95.48%	82.44%	76.34%	94.78%	105.52%	110.14%	108.22%	124.06%	116.74%	117.86%	113.98%	173.68%	156.25%	100.00%
Research & Development	3.16B	2.54B	3.05B	1.83B	1.75B	1.42B	1.32B	1.05B	996.17M	855.51M	918.78M	806.19M	707.71M	637.42M	550.69M	516.29M	513.05M	371.71M	248.54M	192.16M	199.64M	203.02M	148.67M	84.92M	72.20M	58.70M	51.60M	35.20M	41.50M	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	401.43M	352.58M	289.21M	342.74M	378.20M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	31.40M	24.50M	16.20M	19.60M	58.60M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.14B	944.70M	840.10M	770.46M	658.50M	557.62M	496.08M	432.83M	377.08M	305.41M	362.34M	436.80M	400.72M	187.80M	129.30M	101.91M	84.73M	57.86M	43.99M	42.14M	39.08M	49.39M	47.34M	27.81M	26.10M	18.10M	11.40M	7.90M	7.10M	40.30M	26.70M	13.80M	8.80M	6.40M
Other Expenses	475.50M	-164.80M	4.90M	296.42M	192.18M	-790.00K	-81.38M	4.13M	-6.71M	30.40M	-72.67M	44.99M	124.75M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.30M	4.50M	3.60M	3.20M	3.70M	3.50M	3.90M	2.80M	1.80M	0.00
Operating Expenses	4.78B	3.49B	3.89B	2.60B	2.41B	1.97B	1.82B	1.48B	1.37B	1.16B	1.28B	1.24B	1.11B	825.22M	679.98M	618.20M	597.78M	429.57M	292.53M	234.30M	238.72M	252.41M	196.01M	112.73M	104.60M	81.30M	66.60M	46.30M	52.30M	43.80M	30.60M	16.60M	10.60M	6.40M
Cost & Expenses	6.04B	4.57B	4.80B	3.34B	2.96B	2.38B	2.10B	1.69B	1.50B	1.22B	1.41B	1.52B	1.19B	837.95M	694.18M	633.89M	611.69M	441.74M	302.63M	239.95M	241.84M	280.69M	235.64M	116.81M	101.20M	76.80M	63.00M	43.10M	48.60M	40.30M	26.70M	13.80M	8.80M	6.40M
Interest Income	614.70M	144.60M	4.90M	22.24M	63.68M	0.00	11.75M	0.00	0.00	0.00	0.00	1.94M	1.88M	1.96M	5.01M	16.33M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	44.10M	54.80M	61.50M	58.15M	58.50M	34.12M	57.55M	81.43M	84.21M	72.86M	22.73M	14.71M	36.57M	19.28M	13.19M	13.47M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	181.30M	148.30M	125.60M	109.52M	106.94M	72.42M	61.40M	61.40M	62.34M	63.26M	48.37M	38.19M	35.04M	30.46M	30.11M	32.20M	27.46M	25.87M	27.29M	29.64M	23.44M	25.43M	17.96M	9.10M	6.30M	4.50M	3.60M	3.20M	3.70M	3.50M	3.90M	2.80M	1.80M	0.00
EBITDA	4.61B	4.44B	2.92B	3.28B	1.56B	706.78M	103.26M	75.46M	-411.25M	-598.76M	-554.75M	42.46M	133.94M	-704.89M	-598.88M	-426.19M	-385.21M	-199.52M	-114.45M	-107.59M	-264.53M	-123.05M	-97.14M	-24.65M	-44.30M	-43.20M	-15.60M	-36.30M	-22.80M	-17.20M	5.10M	-7.20M	-3.80M	-4.10M
EBITDA Ratio	46.66%	48.65%	36.82%	51.37%	35.02%	21.76%	12.51%	0.90%	-45.83%	-105.28%	41.63%	0.27%	15.72%	-461.86%	-531.80%	-260.35%	-189.99%	-93.32%	-56.52%	-101.15%	-96.10%	-58.43%	-14.39%	-18.77%	-52.92%	-62.84%	-35.62%	-127.07%	-128.05%	-106.12%	13.26%	-242.11%	-143.75%	-178.26%
Operating Income	4.31B	4.31B	2.78B	2.86B	1.20B	635.15M	123.24M	9.94M	-468.66M	-692.41M	-903.45M	2.33M	113.82M	-696.08M	-613.41M	-462.71M	-419.79M	-229.04M	-149.87M	-154.81M	-264.53M	-119.60M	-91.80M	-38.68M	-39.60M	-32.40M	-19.20M	-29.80M	-26.50M	-20.70M	1.20M	-10.00M	-5.60M	-4.10M
Operating Income Ratio	43.65%	48.23%	36.73%	46.03%	28.77%	20.84%	4.95%	0.58%	-45.40%	-119.30%	-74.54%	0.15%	8.07%	-485.51%	-601.10%	-263.65%	-210.94%	-105.86%	-93.15%	-150.71%	-382.59%	-74.25%	-54.81%	-49.51%	-64.29%	-72.97%	-43.84%	-224.06%	-119.91%	-105.61%	4.30%	-263.16%	-175.00%	-178.26%
Total Other Income/Expenses	72.30M	-75.00M	-51.70M	62.80M	197.42M	-34.91M	-138.93M	-77.30M	-90.92M	-42.46M	-366.11M	-59.11M	-53.38M	-58.55M	-28.17M	2.86M	28.51M	21.10M	-53.55M	-11.44M	67.76M	28.30M	-2.79M	-16.16M	10.30M	0.00	0.00	0.00	5.50M	3.60M	900.00K	2.00M	800.00K	4.10M
Income Before Tax	4.38B	4.23B	2.73B	3.12B	1.39B	600.24M	-15.69M	-67.37M	-559.58M	-734.88M	-976.12M	-12.38M	60.45M	-754.63M	-642.18M	-464.18M	-426.91M	-206.89M	-173.39M	-158.51M	-347.35M	-119.66M	-117.89M	-53.61M	-40.30M	0.00	0.00	-39.50M	-21.00M	-17.10M	2.10M	-8.00M	-4.80M	0.00
Income Before Tax Ratio	44.38%	47.39%	36.05%	50.22%	33.51%	19.70%	-0.63%	-3.96%	-54.21%	-126.61%	-80.54%	-0.81%	4.28%	-526.35%	-629.28%	-264.48%	-214.52%	-95.63%	-107.77%	-154.31%	-502.38%	-74.28%	-70.39%	-68.62%	-65.42%	0.00%	0.00%	-296.99%	-95.02%	-87.24%	7.53%	-210.53%	-150.00%	0.00%
Income Tax Expense	760.20M	910.40M	388.30M	405.15M	218.11M	-1.49B	-107.32M	16.67M	30.38M	6.96M	-288.57M	38.75M	19.27M	19.28M	19.34M	-30.73M	-21.39M	-18.50M	61.68M	29.01M	24.06M	-10.98M	-1.92M	976.00K	1.40M	700.00K	600.00K	10.20M	-5.00M	-3.10M	100.00K	-1.50M	-500.00K	4.30M
Net Income	3.62B	3.32B	2.34B	2.71B	1.18B	2.10B	263.48M	-112.05M	-558.12M	-738.56M	-445.03M	-107.03M	29.57M	-754.63M	-641.58M	-459.85M	-391.28M	-206.89M	-203.42M	-166.25M	-196.77M	-108.62M	-66.23M	-39.66M	-41.00M	-33.10M	-19.80M	-40.00M	-21.50M	-17.60M	2.00M	-8.50M	-5.10M	-4.30M
Net Income Ratio	36.68%	37.20%	30.92%	43.70%	28.27%	68.80%	10.59%	-6.58%	-54.06%	-127.25%	-36.72%	-7.01%	2.10%	-526.35%	-628.70%	-262.02%	-196.61%	-95.63%	-126.43%	-161.85%	-284.59%	-67.43%	-39.54%	-50.76%	-66.56%	-74.55%	-45.21%	-300.75%	-97.29%	-89.80%	7.17%	-223.68%	-159.38%	-186.96%
EPS	14.05	12.97	9.09	10.44	4.58	8.25	1.06	-0.46	-2.32	-3.14	-1.98	-0.50	0.14	-3.77	-3.70	-3.27	-3.03	-1.83	-2.28	-2.12	-2.56	-1.43	-0.89	-0.59	-0.80	-0.65	-0.41	-1.07	-0.63	-0.56	0.08	-0.35	-0.35	-0.33
EPS Diluted	13.89	12.82	9.01	10.29	4.51	8.09	1.04	-0.46	-2.31	-3.14	-1.98	-0.50	0.14	-3.77	-3.70	-3.27	-3.03	-1.83	-2.28	-2.12	-2.56	-1.43	-0.89	-0.59	-0.80	-0.65	-0.41	-1.07	-0.63	-0.56	0.08	-0.35	-0.35	-0.33
Weighted Avg Shares Out	257.70M	256.10M	257.70M	259.84M	256.73M	254.29M	248.86M	243.59M	240.84M	234.92M	224.83M	211.95M	204.89M	200.40M	173.26M	140.56M	128.99M	113.22M	89.24M	78.57M	77.00M	75.75M	74.46M	67.68M	51.04M	50.60M	48.53M	37.38M	34.13M	31.43M	25.00M	24.29M	14.62M	13.03M
Weighted Avg Shares Out (Dil)	260.50M	259.10M	259.90M	263.40M	260.67M	259.19M	253.23M	244.69M	241.31M	235.31M	224.91M	211.95M	208.81M	200.40M	173.26M	140.56M	128.99M	113.22M	89.24M	78.57M	77.00M	75.75M	74.46M	67.68M	51.04M	50.60M	48.53M	37.38M	34.13M	31.43M	25.00M	24.29M	14.62M	13.03M

Prediction: Vertex Pharmaceuticals (VRTX) Could Be The Next Stock Split Stock

October 31, 2024247wallst.com

Companies announce stock splits all the time, and so far this year a number of high profile companies have divvied up their shares into smaller slices.

Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today

October 30, 2024zacks.com

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $475.08, representing a +1% change from its previous close.

Vertex (VRTX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

October 30, 2024zacks.com

Besides Wall Street's top -and-bottom-line estimates for Vertex (VRTX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Vertex Gears Up to Report Q3 Earnings: Is a Beat in the Cards?

October 29, 2024zacks.com

VRTX's revenues in the third quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note

October 28, 2024zacks.com

Vertex Pharmaceuticals (VRTX) closed at $476.37 in the latest trading session, marking a -0.28% move from the prior day.

Top Stocks To Buy Now? 2 Biotech Stocks To Watch

October 28, 2024stockmarket.com

Biotech stocks to keep an eye on in the stock market right now.

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

October 28, 2024zacks.com

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

October 25, 2024businesswire.com

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on multiple kidney diseases in its pipeline including IgA nephropathy (IgAN), primary membranous nephropathy (pMN), and APOL1-mediated kidney disease (AMKD). These updates demonstrate the transformative potential of Vertex's investigational therapies in...